A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Metformin Compared to Metformin Plus Placebo in Subjects in Russia With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Latest Information Update: 17 Feb 2019
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms IMPRESSION
- Sponsors Astellas Pharma Europe Ltd
- 26 Jun 2018 Primary endpoint (Change from baseline in HbA1c with ipragliflozin once daily added on to metformin compared to placebo added on to metformin) has been met, according to the results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.